Molecular Templates (MTEM)
(Real Time Quote from BATS)
$1.27 USD
+0.15 (13.39%)
Updated Sep 11, 2024 03:04 PM ET
NA Value
NA Growth NA Momentum NA VGMIncome Statements
Fiscal Year end for Molecular Templates Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 57 | 20 | 39 | 19 | 22 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 57 | 20 | 39 | 19 | 22 |
Selling & Adminstrative & Depr. & Amort Expenses | 68 | 109 | 119 | 120 | 93 |
Income After Depreciation & Amortization | -10 | -89 | -80 | -101 | -70 |
Non-Operating Income | 5 | 1 | 0 | -2 | 2 |
Interest Expense | 3 | 5 | 3 | 2 | 1 |
Pretax Income | -8 | -93 | -83 | -105 | -69 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -8 | -93 | -83 | -105 | -69 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -8 | -93 | -83 | -105 | -69 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -3 | -80 | -73 | -96 | -69 |
Depreciation & Amortization (Cash Flow) | 7 | 9 | 7 | 4 | 2 |
Income After Depreciation & Amortization | -10 | -89 | -80 | -101 | -70 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 4.50 | 3.76 | 3.69 | 3.18 | 2.52 |
Diluted EPS Before Non-Recurring Items | -2.25 | -24.74 | -22.49 | -31.93 | -18.89 |
Diluted Net EPS (GAAP) | -1.80 | -24.74 | -22.49 | -32.98 | -27.89 |
Fiscal Year end for Molecular Templates Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 0.57 | 11.09 | 7.02 | 6.80 | 6.87 |
Cost Of Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 0.57 | 11.09 | 7.02 | 6.80 | 6.87 |
SG&A, R&D, and Dept/Amort Expenses | 8.87 | 11.14 | 12.39 | 11.93 | 18.61 |
Income After SG&A, R&D, and Dept/Amort Expenses | -8.30 | -0.05 | -5.37 | -5.13 | -11.74 |
Non-Operating Income | 0.24 | 0.65 | 1.45 | 1.02 | 2.06 |
Interest Expense | 0.04 | 0.03 | 0.04 | 0.03 | 1.19 |
Pretax Income | -8.10 | 0.57 | -3.96 | -4.15 | -10.87 |
Income Taxes | -8.10 | 0.00 | -0.01 | 0.00 | 0.00 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | 0.00 | 0.57 | -3.95 | -4.15 | -10.87 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -8.10 | 0.57 | -3.95 | -4.15 | -10.87 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 6.56 | 7.02 | 5.37 | 5.09 | 3.76 |
Diluted EPS Before Non-Recurring Items | -1.23 | 0.08 | -0.73 | -0.82 | -3.30 |
Diluted Net EPS (GAAP) | -1.23 | 0.08 | -0.98 | -0.82 | -2.85 |